Analyst rating
Based on 1 analyst giving stock ratings to GALT in the past 3 months.
EPS
Reported
Estimate
Reported
Estimate
Surprise
Revenue
Reported
Estimate
Reported
Estimate
Surprise
This info isn't a recommendation for what you should personally do, so please don't take the data as investment advice. As with any trade, always look first, then leap. Read more in the Terms of Use.
Frequently Asked Questions
GALT EPS for the last quarter is −0.19 USD despite the estimation of −0.16 USD. In the next quarter EPS is expected to reach −0.20 USD. Track more of Galectin Therapeutics Inc. financials and stay on top of what is up with the company.